TapImmune Inc. Share Price OTC Bulletin Board
Stocks
US8760332002
Biotechnology & Medical Research
|
End-of-day quote
OTC Bulletin Board
|
||
| - USD | - |
|
| Market Cap | 2.03Cr 1.79Cr 1.68Cr 1.53Cr 2.87Cr 194.85Cr 2.89Cr 20Cr 7.81Cr 99Cr 7.64Cr 7.47Cr 322.09Cr | P/E 2026 * |
-2.06x | P/E 2027 * | -1.39x |
|---|---|---|---|---|---|
| Enterprise Value | 2.03Cr 1.79Cr 1.68Cr 1.53Cr 2.87Cr 194.85Cr 2.89Cr 20Cr 7.81Cr 99Cr 7.64Cr 7.47Cr 322.09Cr | EV / Sales 2026 * |
4.8x | EV / Sales 2027 * | 1.01x |
| Free-Float |
94.51% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: TapImmune Inc.
| 21/21/21 | Wall Street hoger gesloten | |
| 20/21/20 | Wall Street koerst af op hoger slot | |
| 20/21/20 | Wall Street richting lagere opening |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 46 | 01/05/2023 |
| Chief Operating Officer | 36 | 01/12/2023 | |
Patricia Allison
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Juan Vera
BRD | Director/Board Member | 46 | 17/10/2018 |
Norman Eansor
CHM | Chairman | 65 | 24/05/2022 |
Steven Elms
BRD | Director/Board Member | 62 | 06/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | +4.35% | +4.23% | +30.02% | 4.79TCr | |
| -0.75% | -0.27% | +43.79% | +32.46% | 4.45TCr | |
| -0.95% | +4.71% | +10.75% | +91.44% | 4.19TCr | |
| -0.99% | -2.17% | +333.57% | +549.69% | 4.13TCr | |
| -0.62% | -0.06% | +10.15% | +46.02% | 3TCr | |
| -1.82% | +0.15% | +24.43% | +152.29% | 1.76TCr | |
| -5.59% | -8.87% | - | - | 1.56TCr | |
| -3.55% | +1.95% | +21.97% | +39.13% | 1.57TCr | |
| -1.56% | +8.72% | -9.58% | - | 1.39TCr | |
| Average | -1.78% | +2.66% | +54.92% | +134.44% | 2.98TCr | |
| Weighted average by Cap. | -1.27% | +1.88% | +68.58% | +142.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 42.42L 37.23L 35L 32L 59.79L 41Cr 60.24L 4.2Cr 1.63Cr 21Cr 1.59Cr 1.56Cr 67Cr | 2.02Cr 1.77Cr 1.67Cr 1.52Cr 2.85Cr 193.36Cr 2.87Cr 20Cr 7.75Cr 99Cr 7.58Cr 7.41Cr 319.63Cr |
| Net income | -1.18Cr -1.04Cr -97.65L -89.28L -1.67Cr -113.38Cr -1.68Cr -12Cr -4.55Cr -58Cr -4.44Cr -4.35Cr -187.42Cr | -1.81Cr -1.59Cr -1.49Cr -1.36Cr -2.55Cr -173.3Cr -2.57Cr -18Cr -6.95Cr -88Cr -6.79Cr -6.65Cr -286.47Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
